Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CFO Sells 61,859 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP CFO Joseph M. Miller sold 61,859 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the sale, the chief financial officer now directly owns 633,515 shares in the company, valued at approximately $5,068,120. The trade was a 8.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Aurinia Pharmaceuticals Stock Down 0.5 %

Aurinia Pharmaceuticals stock traded down $0.04 during midday trading on Friday, hitting $8.15. The stock had a trading volume of 1,152,887 shares, compared to its average volume of 1,481,486. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.17 billion, a P/E ratio of -54.33 and a beta of 1.22. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67. The business has a fifty day moving average price of $8.08 and a 200 day moving average price of $7.87.

Analysts Set New Price Targets

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 19th.

Remove Ads

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Aurinia Pharmaceuticals by 21.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 363,674 shares of the biotechnology company's stock valued at $3,266,000 after purchasing an additional 65,220 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Aurinia Pharmaceuticals by 69.7% during the fourth quarter. Woodline Partners LP now owns 849,477 shares of the biotechnology company's stock valued at $7,628,000 after purchasing an additional 348,983 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Tang Capital Management LLC grew its holdings in shares of Aurinia Pharmaceuticals by 16.6% during the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock valued at $75,697,000 after purchasing an additional 1,200,000 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.